Profile

Karl-Erik Andersson, M.D., Ph.D.Wake Forest School of Medicine

Karl-Erik Andersson, M.D., Ph.D.

Professor,



Contact Information

Academic: 336-713-1195 | Department: 336-716-2011

Email: keanders@wakehealth.edu

Education & Training

  • M.D., Lund University Fac Med-Sweden , 1968
Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.

Professor, Institute for Regenerative Medicine
Molecular Medicine
Physiology & Pharmacology
Urology

Research Interests

drugs/therapeutic agents pharm, women's health issues

Contact Information

Academic: 336-713-1195 | Department: 336-716-2011

Email: keanders@wakehealth.edu

Recent Publications

Andersson KE. Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol. 2015;25(1):12-18.

Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder?. Neurourol Urodyn. 2014;33(1):9-16.

Chapple CR, Abrams P, Andersson KE, Radziszewski P, Masuda T, Small M, Kuwayama T, Deacon S. Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539 for nonneurogenic overactive bladder syndrome. J Urol. 2014;191(1):253-260.

Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol Urodyn. 2014;33(1):54-58.

Fullhase C, Campeau L, Sibaev A, Storr M, Hennenberg M, Gratzke C, Stief C, Hedlund P, Andersson KE. Bladder function in a cannabinoid receptor type 1 knockout mouse. BJU Int. 2014;113(1):144-151.

Andersson KE. Bladder underactivity [editorial]. Eur Urol. 2014;65(2):399-401.

Campeau L, Soler R, Sittadjody S, Pareta R, Nomiya M, Zarifpour M, Opara EC, Yoo JJ, Andersson KE. Effects of allogeneic bone marrow derived mesenchymal stromal cell therapy on voiding function in a rat model of Parkinson disease. J Urol. 2014;191(3):850-859.

Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981-990.

Zarifpour M, Sandberg J, Abolbashari M, Vadhavkar M, Kelkar S, Mohs A, Marini F, Andersson KE, Christ G. Characterization of functional bladder regeneration in mice [abstract]. Neurourol Urodyn. 2014;33(2):186.

Van Kerrebroeck P, Andersson KE. Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn. 2014;33(Suppl 1):S2-S5.

Campeau L, Fullhase C, Sawada N, Gratzke C, Hedlund P, Howlett AC, Andersson KE. Characterization of bladder function in a cannabinoid receptor type 2 knockout mouse in vivo and in vitro. Neurourol Urodyn. 2014;33(5):566-570.

Colaco M, Koslov DS, Keys T, Evans RJ, Badlani GH, Andersson KE, Walker SJ. Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. J Urol. 2014;192(4):1123-1129.

Kim J, Andersson KE, Jackson JD, Lee SJ, Atala A, Yoo JJ. Downregulation of metabolic activity increases cell survival under hypoxic conditions: potential applications for tissue engineering. Tissue Eng Part A. 2014;20(15-16):2265-2272.

Nomiya M, Yamaguchi O, Akaihata H, Hata J, Sawada N, Kojima Y, Andersson KE. Progressive vascular damage may lead to bladder underactivity in rats. J Urol. 2014;191(5):1462-1469.

Andersson KE. The many faces of impaired bladder emptying. Curr Opin Urol. 2014;24(4):363-369.

Andersson KE. Current and future drugs for treatment of MS-associated bladder dysfunction. Ann Phys Rehabil Med. 2014;57(5):321-328.

Hanna-Mitchell AT, Kashyap M, Chan WV, Andersson KE, Tannenbaum C. Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Neurourol Urodyn. 2014;33(5):611-617.

Kunit T, Gratzke C, Schreiber A, Strittmatter F, Waidelich R, Rutz B, Loidl W, Andersson KE, Stief CG, Hennenberg M. Inhibition of smooth muscle force generation by focal adhesion kinase inhibitors in the hyperplastic human prostate. Am J Physiol Renal Physiol. 2014;307(7):F823-F832.


Williams JK, Andersson K. A comparison of cellular and acellular (chemokine) therapy in a primate model of urinary sphincter deficiency [abstract]. Neurourol Urodyn. 2014;33(6):835-836.

Drumm BT, Koh SD, Andersson KE, Ward SM. Calcium signalling in Cajal-like interstitial cells of the lower urinary tract. Nat Rev Urol. 2014;11(10):555-564.

Jackson JR, Kim N, Kim J, Andersson KE, Yoo J, Atala A. Induction and maintenance of cellular hypometabolsm for improved tissue survival for reconstructive procedures [abstract]. J Am Coll Surg. 2014;219(3 Suppl):S142.

Tremp M, Salemi S, Largo R, Andersson KE, A Plock J, Aboushwareb T, Sulser T, Eberli D. Adipose-derived stem cells (ADSCs) and muscle precursor cells (MPCs) for the treatment of bladder voiding dysfunction. World J Urol. 2014;32(5):1241-1248.




Ishizuka O, Imamura T, Kurizaki Y, Nishizawa O, Andersson KE. Male lower urinary tract symptoms and alpha1D-adrenoceptors. Int J Urol. 2013;20(1):73-78.

Kurizaki Y, Ishizuka O, Imamura T, Ishikawa M, Ichino M, Ogawa T, Nishizawa O, Andersson KE. Relationship between expression of beta3-adrenoceptor mRNA in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Neurourol Urodyn. 2013;32(1):88-91.

Ochodnicky P, Uvelius B, Andersson KE, Michel MC. Autonomic nervous control of the urinary bladder. Acta Physiol (Oxf). 2013;207(1):16-33.

Horst M, Heutschi J, van den Brand R, Andersson KE, Gobet R, Sulser T, Courtine G, Eberli D. Multisystem neuroprosthetic training improves bladder function after severe spinal cord injury. J Urol. 2013;189(2):747-753.


Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Keys T, Peyton C, Yamaguchi O, Andersson KE. Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol. 2013;189(2):754-761.

Campeau L, Hicks A, Burmeister D, Bishop C, Andersson KE. Lack of nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2)- consequences for mouse bladder development and function [abstract]. Neurourol Urodyn. 2013;32(2):130.

Nomiya M, Sawada N, Zarifpour M, Andersson KE. Effect of melatonin on chronic bladder ischemia associated changes in rat bladder function [abstract]. Neurourol Urodyn. 2013;32(2):134-135.


Badra S, Andersson KE, Dean A, Mourad S, Williams JK. A nonhuman primate model of stable urinary sphincter deficiency. J Urol. 2013;189(5):1967-1974.


Birder L, Andersson K-E. Urothelial signaling. Physiol Rev. 2013;93(2):653-680.

Chen J, Gu B, Wu G, Tu H, Si J, Xu Y, Andersson K-E. The effect of the 5-HT2A/2C receptor agonist DOI on micturition in rats with chronic spinal cord injury. J Urol. 2013;189(5):1982-1988.

Christ GJ, Saul JM, Furth ME, Andersson KE. The pharmacology of regenerative medicine. Pharmacol Rev. 2013;65(3):1091-1133.

Fullhase C, Russo A, Castiglione F, Benigni F, Campeau L, Montorsi F, Gratzke C, Bettiga A, Stief C, Andersson KE, Hedlund P. Spinal cord FAAH in normal micturition control and bladder overactivity in awake rats. J Urol. 2013;189(6):2364-2370.

Noguchi W, Ishizuka O, Imamura T, Kurizaki Y, Yamagishi T, Yokoyama H, Lei Z, Silwal SG, Nishizawa O, Andersson KE. Relationship between alpha1-adrenergic receptors and TRPM8 channels in detrusor overactivity induced by cold stress in ovariectomized rats. J Urol. 2013;189(5):1975-1981.

Sunagawa M, Wolf-Johnston A, Nomiya M, Sawada N, Andersson KE, Hisamitsu T, Birder LA. Urothelial-neural responses to chronic bladder ischemia [abstract]. FASEB J. 2013;27():lb500.

Lei Z, Ishizuka O, Imamura T, Noguchi W, Yamagishi T, Yokoyama H, Kurizaki Y, Sudha GS, Hosoda T, Nishizawa O, Andersson KE. Functional roles of transient receptor potential melastatin 8 (TRPM8) channels in the cold stress-induced detrusor overactivity pathways in conscious rats. Neurourol Urodyn. 2013;32(5):500-504.

Nomiya M, Akaihata H, Takahashi N, Aikawa K, Sawada N, Andersson K, Yamaguchi O, Kojima Y. Progression of vascular damage and bladder dysfunction in rats [abstract]. Neurourol Urodyn. 2013;32(6):842-843.

Nomiya M, Burmeister DM, Sawada N, Campeau L, Zarifpour M, Yamaguchi O, Andersson KE. Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function. BJU Int. 2013;112(2):E221-E230.

Koslov DS, Andersson KE. Physiological and pharmacological aspects of the vas deferens-an update. Front Pharmacol. 2013;4():101.

Sawada N, Nomiya M, Hood B, Koslov D, Zarifpour M, Andersson KE. Protective effect of a beta3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol. 2013;64(4):664-671.

Hicks AN, Campeau L, Burmeister D, Bishop CE, Andersson KE. Lack of nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2): consequences for mouse bladder development and function. Neurourol Urodyn. 2013;32(8):1130-1136.

Andersson KE, Martin N, Nitti V. Selective beta3-adrenoceptor agonists for the treatment of overactive bladder. J Urol. 2013;190(4):1173-1180.



Soler R, Andersson KE, Chancellor MB, Chapple CR, de Groat WC, Drake MJ, Gratzke C, Lee R, Cruz F. Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol. 2013;64(4):610-621.

Fullhase C, Hennenberg M, Giese A, Schmidt M, Strittmatter F, Soler R, Gratzke C, Andersson KE, Stief C. Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol. 2013;190(4):1430-1435.

Burmeister DM, AbouShwareb T, Bergman CR, Andersson KE, Christ GJ. Age-related alterations in regeneration of the urinary bladder after subtotal cystectomy. Am J Pathol. 2013;183(5):1585-1595.

Hennenberg M, Miljak M, Herrmann D, Strittmatter F, Walther S, Rutz B, Hocaoglu Y, Kunit T, Schreiber A, Andersson KE, Stief CG, Gratzke C. The receptor antagonist picotamide inhibits adrenergic and thromboxane-induced contraction of hyperplastic human prostate smooth muscle. Am J Physiol Renal Physiol. 2013;305(10):F1383-1390.

Andersson KE. Future therapies: early trials and basic science. Can Urol Assoc J. 2013;7(9-10 Suppl 4):S179-S180.


Gu B, Wu G, Si J, Xu Y, Andersson K-E. Improving voiding efficiency in the diabetic rat by a 5-HT1A serotonin receptor agonist. Neurourol Urodyn. 2012;31(1):168-173.

Nomiya M, Sagawa K, Yazaki J, Takahashi N, Kushida N, Haga N, Aikawa K, Matsui T, Oka M, Fukui T, Andersson K-E, Yamaguchi O. Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol Urodyn. 2012;31(1):185-189.

Nomiya M, Yamaguchi O, Andersson K-E, Sagawa K, Aikawa K, Shishido K, Yanagida T, Kushida N, Yazaki J, Takahashi N. The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. Neurourol Urodyn. 2012;31(1):195-200.

Soler R, Fullhase C, Hanson A, Campeau L, Santos C, Andersson K-E. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol. 2012;187(4):1491-1497.

Andersson K-E, Wein AJ. Pharmacologic management of lower urinary tract storage and emptying failure In: Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh urology, vol 3. 10th ed. Philadelphia: Elsevier Saunders;2012: 1967-2002.

Campeau L, Soler R, Nomiya M, Andersson KE. Rat bone marrow derived mesenchymal stem cell therapy in a Parkinsonian animal model of detrusor overactivity [abstract]. Neurourol Urodyn. 2012;31(2):240.

Keys T, Gorbachinsky I, Mckenzie P, Campeau L, Rohozinski J, Andersson K-E, Langefeld C, Badlani G. Enhanced MMP-1 transcription: role in the development of SUI and POP [abstract]. Neurourol Urodyn. 2012;31(2):244.

Hanno P, Andersson KE, Birder L, Elneil S, Kanai A, Pontari M. Chronic pelvic pain syndrome/bladder pain syndrome: taking stock, looking ahead: ICI-RS 2011. Neurourol Urodyn. 2012;31(3):375-383.

Kanai A, Zabbarova I, Oefelein M, Radziszewski P, Ikeda Y, Andersson K-E. Mechanisms of action of botulinum neurotoxins, beta3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn. 2012;31(3):300-308.


Malykhina AP, Wyndaele J-J, Andersson K-E, De Wachter S, Dmochowski RR. Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn. 2012;31(3):352-358.

Campeau L, Soler R, Nomiya M, Andersson KE. Rat bone marrow derived mesenchymal stem cell therapy in a Parkinsonian animal model of detrusor overactivity [abstract]. Eur Urol Suppl. 2012;11(1):e1070-70a.

Gandaglia G, Benigni F, La Croce G, Moschini M, Strittmatter F, Colli E, Andersson KE, Hedlund P. Degarelix reduces urodynamic changes in a rat model for experimental detrusor overactivity and causes more efficient voiding [abstract]. Eur Urol Suppl. 2012;11(1):e741-741a.

Hennenberg M, Strittmatter F, Beckmann C, Walther S, Rutz B, Bartesch C, Roosen A, Hedlund P, Andersson KE, Stief CG, Gratzke C. Alpha1-adrenoceptors in the human prostate activate the transcription factors Elk1 and SRF [abstract]. Eur Urol Suppl. 2012;11(1):e7-e7a.

Strittmatter F, Walther S, Gratzke C, Gottinger J, Roosen A, Schlenker B, Beckmann C, Hedlund P, Andersson KE, Stief G, Hennenberg M. The JNK inhibitors SP600125 and BI-78D3 inhibit the alpha1-adrenergic contraction of human prostate tissue [abstract]. Eur Urol Suppl. 2012;11(1):e3-e3a.

Burmeister D, AbouShwareb T, D'Agostino R Jr, Andersson K-E, Christ GJ. Impact of partial urethral obstruction on bladder function: time-dependent changes and functional correlates of altered expression of Ca2+ signaling regulators. Am J Physiol Renal Physiol. 2012;302(12):F1517-28.


Strittmatter F, Walther S, Gratzke C, Gottinger J, Beckmann C, Roosen A, Schlenker B, Hedlund P, Andersson KE, Stief CG, Hennenberg M. Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3. Br J Pharmacol. 2012;166(6):1926-1935.

Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction. BJU Int. 2012;110(2 Pt 2):E125-E131.

Bharadwaj S, Liu GH, Wu S, Andersson K-E, Atala A, Zhang Y. Biological characterization of human urine-derived stem cells from the upper urinary tract for potential use in bladder regeneration in patients with end-stage bladder disease [abstract]. J Tissue Eng Regen Med. 2012;6(Suppl 1):132.

Kim J, Hwang A, Khouri R, Andersson K-E, Lee SJ, Jackson J, Atala A, Yoo J. Down-regulation of cellular metabolism improves cell survival under hypoxic conditions [abstract]. J Tissue Eng Regen Med. 2012;6(Suppl 1):275.

Shi YA, Liu GH, Bharadwaj S, Markert C, Atala A, Zhang Y. Urine derived stem cells with high telomerase activity: an optimized cell source for regenerative medicine in urology [abstract]. J Tissue Eng Regen Med. 2012;6(Suppl 1):132.

Hicks AN, Lorenzetti D, Gilley J, Lu B, Andersson KE, Miligan C, Overbeek PA, Oppenheim R, Bishop CE. Nicotinamide mononucleotide adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS One. 2012;7(10):e47869.


Burmeister D, Peyton C, Aboushwareb T, Bergman C, Andersson K-E, Christ G. Age-dependent impairments in rat bladder regeneration [abstract]. FASEB J. 2012;26(Meeting Abstracts Suppl):198.3.

Hennenberg M, Strittmatter F, Beckmann C, Rutz B, Fullhase C, Waidelich R, Montorsi F, Hedlund P, Andersson KE, Stief CG, Gratzke C. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle. PLoS One. 2012;7(11):e50904.

Gratzke C, Streng T, Stief CG, Alroy I, Limberg BJ, Downs TR, Rosenbaum JS, Hedlund P, Andersson K-E. Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J Urol. 2011;185(2):731-736.

Campeau L, Gorbachinsky I, Ziegler JT, Langefeld CD, Andersson KE, Rohozinski J, Badlani G. Comparison of MMP-1 enzymatic activity and TIMP-1 inhibition in women with pelvic organ prolapse [abstract]. Neurourol Urodyn. 2011;30(2):240-241.

Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011;202():319-344.

Abdel-Hamid IA, Andersson KE, Salonia A. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories. Expert Opin Ther Targets. 2011;15(3):325-340.

Aizawa N, Igawa Y, Andersson K-E, Iijima K, Nishizawa O, Wyndaele J-J. Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin-sensitivity. Neurourol Urodyn. 2011;30(1):163-168.

Andersson K-E, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30(3):292-301.

Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011;59(3):377-386.

Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson K-E. Relation between expression of alpha1-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011;45(1):15-19.

Soler R, Fullhase C, Santos C, Andersson K-E. Development of bladder dysfunction in a rat model of dopaminergic brain lesion. Neurourol Urodyn. 2011;30(1):188-193.

Thuroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schroder A, Tubaro A. EAU guidelines on urinary incontinence. Eur Urol. 2011;59(3):387-400.

Russo A, Castiglione F, Salonia A, Benigni F, Andersson KE, Hedlund P. Effects by the GNRH antagonist ganirelix on normal micturition and PGE2-induced detrusor overactivity in conscious female rats [abstract]. Eur Urol Suppl. 2011;10(2):256-257.

Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, Andersson K-E, Hedlund P. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E2-induced detrusor overactivity in conscious female rats. Eur Urol. 2011;59(5):868-874.

Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Elocalcitol improves effects by tolterodine in rats with partial urethral obstruction [abstract]. Eur Urol Suppl. 2011;10(2):181-182.

Andersson K-E, Soler R, Fullhase C. Rodent models for urodynamic investigation. Neurourol Urodyn. 2011;30(5):636-646.

Kanai A, Wyndaele J-J, Andersson K-E, Fry C, Ikeda Y, Zabbarova I, De Wachter S. Researching bladder afferents--determining the effects of beta3-adrenergic receptor agonists and botulinum toxin type-A. Neurourol Urodyn. 2011;30(5):684-691.

Strittmatter F, Gratzke C, Weinhold P, Steib CJ, Hartmann AC, Schlenker B, Andersson K-E, Hedlund P, Stief CG, Hennenberg M. Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms. Eur J Pharmacol. 2011;650(2-3):650-655.

van Koeveringe GA, Vahabi B, Andersson KE, Kirschner-Herrmans R, Oelke M. Detrusor underactivity: a plea for new approaches to a common bladder dysfunction. Neurourol Urodyn. 2011;30(5):723-728.

Nielsen JS, Rode F, Rahbek M, Andersson K-E, Ronn LC, Bouchelouche K, Nordling J, Bouchelouche P. Effect of the SK/IK channel modulator 4,5-dichloro-1,3-diethyl-1,3-dihydro-benzoimidazol-2-one (NS4591) on contractile force in rat, pig and human detrusor smooth muscle. BJU Int. 2011;108(5):771-777.

Bharadwaj S, Liu G, Shi Y, Markert C, Andersson K-E, Atala A, Zhang Y. Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A. 2011;17(15-16):2123-2132.

Andersson K-E, Campeau L, Olshansky B. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction. Br J Clin Pharmacol. 2011;72(2):186-196.

Aizawa N, Iijima K, Rosenbaum JS, Downs TR, Igawa Y, Andersson K-E, Wyndaele J-J. Comparison of the effects of oestrogen deficiency and old age on primary bladder afferent activity and voiding behaviour in the ageing female rat. BJU Int. 2011;108(2B):E10-E16.

Bauer RM, Strittmatter F, Gratzke C, Gottinger J, Schlenker B, Reich O, Stief CG, Hedlund P, Andersson K-E, Hennenberg M. Coupling of alpha1-adrenoceptors to ERK1/2 in the human prostate. Urol Int. 2011;86(4):427-433.

Thuroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schroder A, Tubaro A. [EAU guidelines on urinary incontinence] [Spanish]. Actas Urol Esp. 2011;35(7):373-388.

Andersson K-E, Abdel-Hamid IA. Therapeutic targets for premature ejaculation. Maturitas. 2011;70(1):26-33.

Campeau L, Gorbachinsky I, Badlani GH, Andersson KE. Pelvic floor disorders: linking genetic risk factors to biochemical changes. BJU Int. 2011;108(8):1240-1247.

Hennenberg M, Strittmatter F, Walther S, Hedlund P, Andersson K-E, Stief CG, Schlenker B, Gratzke C. Alpha 1-adrenoceptor activation induces phosphorylation of beta 2-adrenoceptors in human prostate tissue. BJU Int. 2011;108(6):922-928.

Andersson K-E. Drugs and future candidates. Can Urol Assoc J. 2011;5(5 Suppl 2):S131-S133.


Mangera A, Andersson K-E, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, Gravas S, Madersbacher S. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA). Eur Urol. 2011;60(4):784-795.


Jin L-H, Andersson K-E, Han J-U, Kwon Y-H, Park C-S, Shin H-Y, Yoon S-M, Lee T. Persistent detrusor overactivity in rats after relief of partial urethral obstruction. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R896-904.

Campeau L, Soler R, Andersson K-E. Bladder dysfunction and Parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep. 2011;12(6):396-403.

Hicks A, Lorenzetti D, Lu B, Andersson K-E, Overbeek P, Oppenheim R, Bishop C. Nervous system defects in the novel bloated bladder mouse mutant (BLAD) [abstract]. Soc Neurosci Abstr. 2011;2011(Neuroscience Meeting Planner):33.15.


Andersson K-E. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010;29(1):97-106.


Soler R, Fullhase C [Fuellhase C], Lu B, Bishop CE, Andersson K-E. Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide?. J Urol. 2010;183(2):780-785.

Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson K-E, Hedlund P. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010;57(5):902-910.

Chen Z, Ishizuka O, Imamura T, Aizawa N, Kuriazki Y, Igawa Y, Nishizawa O, Andersson K-E. Stimulation of skin menthol receptors stimulates detrusor activity in conscious rats. Neurourol Urodyn. 2010;29(3):506-511.

Kanai A, Andersson K-E. Bladder afferent signaling: recent findings. J Urol. 2010;183(4):1288-1295.

Weinhold P, Gratzke C, Streng T, Stief C, Andersson K-E, Hedlund P. TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation. J Urol. 2010;183(5):2070-2076.

Gratzke C, Streng T, Stief CG, Downs TR, Alroy I, Rosenbaum JS, Andersson K-E, Hedlund P. Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol. 2010;57(6):1093-1100.

McKenzie P, Rohazinski J, Vishwajit S, Andersson K-E, Badlani G. Mmp-1 promoter variant is associated with stress urinary incontinence and pelvic organ prolapse [abstract]. Neurourol Urodyn. 2010;29(2):255-256.

Russo A, Castiglione F, Andersson KE, Gustafsson JA, Hedlund P. Nitric oxide-, CGMP- & PGK1-mediated relaxation of the mouse vagina is coupled to the alpha estrogen receptor [abstract]. J Sex Med. 2010;7(Suppl 3):130.

Christ GJ, Melman A, Williams K, Aboushwareb T, Zhao WX, Kaplan J, Anderson K-E [sic] [Andersson K-E]. Nonhuman primates as a model for translational research on atherosclerosis-related vascular disease and erectile dysfunction [abstract]. J Sex Med. 2010;7(Suppl 1):46.

Fullhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010;106(2):287-293.

Zhao W, Aboushwareb T, Turner C, Mathis C, Bennett C, Sonntag WE, Andersson K-E, Christ G. Impaired bladder function in aging male rats. J Urol. 2010;184(1):378-385.

Andersson K-E, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010;106(2):268-274.

Fullhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. J Urol. 2010;184(2):783-789.

Burmeister D, AbouShwareb T, Tan J, Link K, Andersson K-E, Christ G. Early stages of in situ bladder regeneration in a rodent model. Tissue Eng Part A. 2010;16(8):2541-2551.


Soler R, Fullhase C, Hanson A, Andersson K, Santos C. Effect of amniotic fluid and bone marrow stem cell therapy on bladder dysfunction in a Parkinson's disease model [abstract]. Int Urogynecol J. 2010;21(Suppl 1):S384-S385.


Burnett AL, Goldstein I, Andersson KE, Argiolas A, Christ G, Park K, Xin ZC. Future sexual medicine physiological treatment targets. J Sex Med. 2010;7(10):3269-3304.

Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572-3588.

Streng T, Santti R, Andersson K-E. Voiding effects mediated by alpha2-adrenoceptors in the anaesthetized male rat. BJU Int. 2010;106(10):1546-1549.

Limberg BJ, Andersson K-E, Kullmann FA, Burmer G, de Groat WC, Rosenbaum JS. Beta-adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010;342(2):295-306.


Jin L-H, Andersson K-E, Kwon Y-H, Park C-S, Yoon S-M, Lee T. Substantial detrusor overactivity in conscious spontaneously hypertensive rats with hyperactive behaviour. Scand J Urol Nephrol. 2009;43():3-7.

Vishwajit S, Anderson KE [sic] [Andersson KE]. Terminology of lower urinary tract symptoms. Helpful or confusing?. ScientificWorldJournal. 2009;9():17-22.

Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets. 2009;13(2):175-193.

Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P, Andersson K-E. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol. 2009;181(4):1939-1948.

Gratzke C, Streng T, Waldkirch E, Sigl K, Stief C, Andersson K-E, Hedlund P. Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region. Eur Urol. 2009;55(3):696-704.

Chen Z, Ishizuka O, Imamura T, Aizawa N, Igawa Y, Nishizawa O, Andersson K-E. Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats. Neurourol Urodyn. 2009;28(3):251-256.

Soler R, Fullhase C [Fuellhase C], Santos CC, Vishwajit S, Badlani GH, Andersson K-E. Bladder dysfunction in an acute experimental model of unilateral dopaminergic neurons lesion [abstract]. J Urol. 2009;181(4 Suppl):336.

Vishwajit S, Rohozinski J, Andersson K-E, Badlani GH. Association of MMP1 promoter variant with stress urinary incontinence and pelvic organ prolapse in women [abstract]. J Urol. 2009;181(4 Suppl):481.

Eberli D, Andersson KE, Yoo JJ, Atala A. A canine model of irreversible urethral sphincter insufficiency. BJU Int. 2009;103(2):248-253.

Fuellhase C, Soler R, Andersson KE, Atala A, Yoo JJ. Generation of organized bladder tissue constructs using a novel hybrid printing system [abstract]. Eur Urol Suppl. 2009;8(4):186.

Fullhase C [Fuellhase C], Soler R, Lu B, Bishop CE, Andersson KE. Increased levels of superoxide ions affects bladder function in a new mutant mouse model [abstract]. Eur Urol Suppl. 2009;8(4):176.

Gratzke C, Weinhold P, Reich O, Stief CG, Andersson KE, Hedlund P. Distribution and function of transient receptor potential ion channel A1 and cannabinoid receptors in the human prostate [abstract]. Eur Urol Suppl. 2009;8(4):190.

Gratzke C, Weinhold P, Selwood D, Stief CG, Andersson KE, Hedlund P. Distribution of the G-protein-coupled receptor 55 (GPR55) in the rat bladder and urodynamic effects of a selective GPR55-agonist in conscious rats [abstract]. Eur Urol Suppl. 2009;8(4):271.

Soler R, Fuellhase C, Andersson KE, Yoo JJ. The effect of lamina propria cells on the growth of urothelial and smooth muscle cells [abstract]. Eur Urol Suppl. 2009;8(4):188.

Streng T, Hedlund H, Svalheim S, Talo A, Solend CM, Andersson KE, Hedlund P. Bladder electrical activity during cystometry: application from rat to human [abstract]. Eur Urol Suppl. 2009;8(4):243.

Weinhold P, Hedlund P, Reich O, Stief CG, Andersson KE, Gratzke C. Transient receptor potential A1 (TRPA1) agonists decrease nerve-mediated responses of the human ureter [abstract]. Eur Urol Suppl. 2009;8(4):206.

Weinhold P, Gratzke C, Streng T, Andersson KE, Hedlund P. TRPA1-receptor-induced relaxation of the human urethra involves TRPV1-and cannabinoid-receptor-mediated signals and activation of cyclooxygenases [abstract]. Eur Urol Suppl. 2009;8(4):270.

Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009;19(4):380-394.

Zhao W, Sato Y, Melman A, Andersson KE, Christ G. Metrics for evaluation of age-related changes in erectile capacity in a rodent model. J Sex Med. 2009;6(7):1885-1892.


Imamura T, Ishizuka O, Zhong C, Ogawa T, Nakayama T, Kurizaki Y, Tanabe T, Nishizawa O, Andersson K-E. An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats. Neurourol Urodyn. 2009;28(6):529-534.

Aboushwareb T, Zhou G, Deng F-M, Turner C, Andersson K-E, Tar M, Zhao W, D'Agostino R Jr, Sun T-T, Christ GJ, et al. Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice. Neurourol Urodyn. 2009;28(8):1028-1033.

Kim J, Asche C, Kahler K, Kulkarni A, Andersson KE. Assessment of cardiovascular (CV) comorbidity in patients with overactive bladder (OAB) [abstract]. Pharmacoepidemiol Drug Saf. 2009;18(Suppl 1):S241-S242.

Aizawa N, Iijima K, Rosenbaum J, Downs TR, Igawa Y, Andersson K, Wyndaele JJ. Effects of estrogen deficiency and its replacement on voiding behaviour and primary bladder afferent activity in the rat [abstract]. Neurourol Urodyn. 2009;28(7):800-802.

Burmeister D, AbouShwareb T, Andersson K, Christ G. Establishing a rodent model for characterization of natural in vivo bladder regeneration [abstract]. Neurourol Urodyn. 2009;28(7):739-741.

Ishizuka O, Chen Z, Imamura T, Aizawa N, Kurizaki Y, Igawa Y, Nishizawa O, Andersson K. Stimulation of cold stress skin receptor: transient receptor potential melastatin 8 (TRPM8) causes sudden urinary frequency in normal conscious rats [abstract]. Neurourol Urodyn. 2009;28(7):750-752.

Soler R, Fuellhase C, Lu B, Bishop C, Andersson K. Bladder dysfunction in a new animal model of increased levels of superoxide ions [abstract]. Neurourol Urodyn. 2009;28(7):809-810.

Christ GJ, Andersson K-E, Williams K, Zhao W, D'Agostino R Jr, Kaplan J, Aboushwareb T, Yoo J, Calenda G, Davies KP, et al. Smooth-muscle-specific gene transfer with the human Maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol. 2009;56(6):1055-1066.

Abdel-Hamid IA, Andersson KE. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. Pharmacogenomics. 2009;10(10):1625-1644.

Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009;8(42):118-124.

Andersson KE. When and how do antimuscarinics work in bladder dysfunction, and what's coming up in treatment? [abstract]. Eur J Neurol. 2009;16(Suppl 3):630.

Werkstrom V, Hedlund P, Lee T, Andersson K-E. Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int. 2009;104(11):1740-1745.

Russo A, Castiglione F, Anderson KE [sic] [Andersson KE], Gustafsson JA, Hedlund P. Lack of estrogen receptor alpha alters nerve-mediated contraction and NO/cGMP-mediated relaxation of the mouse vagina [abstract]. J Sex Med. 2009;6(Suppl 5):405-406.

Hipp J, Andersson K-E, Kwon TG, Kwak EK, Yoo J, Atala A. Microarray analysis of exstrophic human bladder smooth muscle. BJU Int. 2008;101(1):100-105.


Streng T, Axelsson HE, Hedlund P, Andersson DA, Jordt S-E, Bevan S, Andersson K-E, Hogestatt ED, Zygmunt PM. Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol. 2008;53(2):391-400.

Aboushwareb T, Burmeister D, Andersson KE, Christ GJ. Novel longitudinal studies of rat bladder regeneration [abstract]. Eur Urol Suppl. 2008;7(3):266.

Christ GJ, Andersson K-E, Williams K, Zhao W, D'Agostino R, Kaplan J, Aboushwareb T, Yoo J, Davies K, Melman A. MAXI-K gene transfer with a smooth muscle specific promoter enhances erectile function and sexual behaviour in atherosclerotic cynomolgous monkeys [abstract]. Eur Urol. 2008;7(3 Suppl):143.

Gratzke C, Christ GJ, Kaplan JR, Stief CG, Andersson KE, Badlani G. Chronic soy and phytoestrogen treatment leads to significant functional and morphological changes in the urethra of oophorectomized female non-human primates [abstract]. Eur Urol. 2008;7(3 Suppl):315.

Gratzke C, Christ GJ, Kaplan JR, Andersson K-E, Badlani G. Chronic soy and phytoestrogen treatment leads to significant functional and morphological changes in the urethra of female non-human primates [abstract]. Neurourol Urodyn. 2008;27(2):106.

Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Micro array analysis of bladder smooth muscle from patients with myelomeningocele [abstract]. Eur Urol. 2008;7(3):229.

Hodges SJ, Zhou G, Deng F-M, Aboushwareb T, Turner C, Andersson K-E, Santago P, Case D, Sun T-T, Christ GJ. Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice. J Urol. 2008;179(5):2046-2051.

Werkstrom V, Lee T, Hedlund P, Andersson KE. Vardenafil relaxes precontracted rat detrusor partially through urothelium-dependent mechanisms [abstract]. Eur Urol. 2008;7(3 Suppl):264.

Zhao W, Machigal M, Turner C, Davies K, Melman A, Andersson KE, Christ GJ. Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2-month streptozotocin (STZ)-diabetic rats [abstract]. Eur Urol. 2008;7(3 Suppl):217.

Lu B, Poirier C, Gaspar T, Gratzke C, Harrison W, Busija D, Matzuk MM, Andersson K-E, Overbeek PA, Bishop CE. A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice. Biol Reprod. 2008;78(4):601-610.

Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stohr T, Andersson K-E. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008;101(8):1036-1042.

Gomez-Pinilla PJ, Gomez MF, Sward K, Hedlund P, Hellstrand P, Camello PJ, Andersson K-E, Pozo MJ. Melatonin restores impaired contractility in aged guinea pig urinary bladder. J Pineal Res. 2008;44(4):416-425.

Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int. 2008;102(6):741-746.

Andersson K-E. How many drugs for LUTS due to BPH are too many? [editorial]. J Urol. 2008;180(3):811-812.


Gratzke C, Jarajapu YPR, Christ GJ, Kaplan JR, Williams JK, Andersson K-E, Badlani G. Effects of long-term dietary soy treatment on female urethral morphology and function in ovariectomized nonhuman primates. J Urol. 2008;180(5):2247-2253.

Gratzke C, Streng T, Waldkirch E, Sigl K, Stief CG, Andersson K, Hedlund P. Transient receptor potential A1 (TRPA1) ion channel activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region [abstract]. Neurourol Urodyn. 2008;27(7 Suppl):599-600.

Igawa Y, Aizawa N, Iijima K, Wyndaele JJ, Andersson K, Nishizawa O. Effects of intravesical capsaicin, resiniferatoxin and ATP on primary bladder afferent activity of the rat [abstract]. Neurourol Urodyn. 2008;27(7 Suppl):709-711.

Zhang Y, McNeill E, Tian H, Soker S, Andersson K-E, Yoo JJ, Atala A. Urine derived cells are a potential source for urological tissue reconstruction. J Urol. 2008;180(5):2226-2233.

Aizawa N, Ishizuka O, Ogawa T, Mizusawa H, Igawa Y, Nishizawa O, Andersson KE. Effects of natriuretic peptides on intracavernous pressure and blood pressure in conscious rats. J Sex Med. 2008;5(10):2312-2317.

Andersson KE, Fullhase C [Fuellhase C], Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008;9(6):459-464.

Delo DM, Eberli D, Williams JK, Andersson K-E, Atala A, Soker S. Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. BJU Int. 2008;102(7):878-884.




Gomez-Pinilla PJ, Gomez MF, Hedlund P, Sward K, Hellstrand P, Camello PJ, Pozo MJ, Andersson K-E. Effect of melatonin on age associated changes in guinea pig bladder function. J Urol. 2007;177(4):1558-1561.

Lee T, Hedlund P, Newgreen D, Andersson K-E. Urodynamic effects of a novel EP1 receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol. 2007;177(4):1562-1567.

Aboushwareb T, Jarajapu YPR, Blaha S, Hodges S, Turner C, Zhao W, Andersson K-E, Christ GJ. Mechanistic studies of detrusor over activity in male rats following partial urethral obstruction: implications to identification of novel therapeutics [abstract]. FASEB J. 2007;21(6):A1356.

Aboushwareb T, Zho G, Turner C, Andersson K-E, Tar M, Melman A, Deng F-M, Sun T-T, Christ GJ. Urodynamic characterization of mice lacking uroplakin II or III [abstract]. FASEB J. 2007;21(6):A1308.

Aboushwareb T, Andersson K-E, Christ GJ. Pharmacological studies of AGI-1140 in a rat model of erectile dysfunction [abstract]. FASEB J. 2007;21(6):A1159-1160.

Andersson KE, Christ GJ. Regenerative pharmacology: the future is now. Mol Interv. 2007;7(2):79-86.

Hodges S, Zhou G, Deng F-M, Abouschwareb T, Turner C, Andersson K-E, Santago P, Sun H, Christ GJ. Voiding patterns in uroplakin II knockout mice [abstract]. FASEB J. 2007;21(6):A1301.

Zhao W, Machingal M, Turner C, Davies K, Andersson K-E, Melman A, Christ GJ. Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2 month streptozotocin(STZ)-diabetic rats [abstract]. FASEB J. 2007;21(5):A420.

Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJG, Andersson K-E, Hedlund P. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha. BJU Int. 2007;99(6):1488-1494.

Sjoqvist F, Eriksson L-O, Andersson K-E. Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden. Eur J Cln Pharmacol. 2007;63(3):229-231.

Aboushwareb TA, Zhou G, Turner C, Andersson KE, Tar M, Melman A, Deng FM, Sun TT, Christ GJ. Urodynamic studies in uroplakin II or III knockout (KO) mice [abstract]. J Urol. 2007;177(4 Suppl):88.

Waldkirch ES, Uckert S, Langnase K, Richter K, Jonas U, Wolf G, Andersson K-E, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol. 2007;52(2):495-502.

Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol. 2007;4(7):368-378.

Hedlund P, Streng T, Lee T, Andersson K-E. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol. 2007;178(1):326-331.

Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007;26(Suppl 6):928-933.

Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007;26(Suppl 6):934-947.

Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007;26(Suppl 6):948-954.

Andersson K, Kahler K, Ebinger U. Prevalence of cardiovascular co-morbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract]. Neurourol Urodyn. 2007;26(5):653-654.

Andersson K, Kahler K, Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract]. Neurourol Urodyn. 2007;26(5):654-655.

Abrams P, Andersson K-E. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007;100(5):987-1006.


Albrecht K, Uckert S, Oelke M, Andersson K-E, Jonas U, Troger H-D, Hedlund P. Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: a potential forensic value?. J Forensic Leg Med. 2007;14(5):270-274.

Abrams P, Andersson K-E, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565-578.


Finney SM, Andersson K-E, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int. 2006;98(3):503-507.

Drake M, Gillespie J, Hedlund P, Harvey I, Lagou M, Andersson K-E. Muscarinic stimulation of the rat isolated whole bladder: pathophysiological models of detrusor overactivity. Auton Autacoid Pharmacol. 2006;26(3):261-266.

Lagou M, De Vente J, Kirkwood TB, Hedlund P, Andersson K-E, Gillespie JI, Drake MJ. Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int. 2006;97(6):1332-1337.

Oelke M, Hedlund P, Albrecht K, Ellinghaus P, Stief CG, Jonas U, Andersson K-E, Uckert S. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study. Urology. 2006;67(5):1111-1116.


Streng T, Hedlund P, Talo A, Andersson K-E, Gillespie JI. Phasic non-micturition contractions in the bladder of the anaesthetized and awake rat. BJU Int. 2006;97(5):1094-1101.

Uckert S, Oelke M, Stief CG, Andersson K-E, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006;49(4):740-745.

Schroder A, Colli E, Maggi M, Andersson K-E. Effects of a vitamin D3 analogue in a rat model of bladder outlet obstruction. BJU Int. 2006;98(3):637-642.

Uckert S, Hedlund P, Andersson K-E, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006;50(6):1194-1207.

Werkstrom V, Svensson A, Andersson K-E, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int. 2006;98(2):414-423.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.